Abstract:A model‐based approach was developed to elucidate etiological differences between and within patient groups representing the two dominant heart failure diagnoses: heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction. A closed‐loop model of the cardiovascular system informed by patient‐specific transthoracic echocardiography (TTE) and right heart catheterization (RHC) data was used to identify key parameters representing cardiovascular mechanics and hemodynamics. Thirty‐one patient records (10 HFrEF, 21 HFpEF) were obtained from the Cardiovascular Health Improvement Project database at the University of Michigan. Model simulations were tuned to match RHC and TTE pressure, volume, and cardiac output measurements in each patient. The underlying physiological model parameters were compared to model‐based norms and between HFrEF and HFpEF diagnoses. Our results confirm the main mechanistic parameter driving HFrEF is reduced left ventricular (LV) contractility, whereas HFpEF exhibits a more heterogeneous phenotype. To determine subgroups within the HFpEF diagnosis, we conducted a principal component analysis on the optimized parameters, which combined with machine learning techniques including k‐means and hierarchical clustering methods reveal (i) a group of HFrEF‐like HFpEF patients (HFpEF1) that share characteristics with HFrEF, (ii) a HFpEF group that exhibit classical characteristics of patients with diastolic dysfunction (HFpEF2), and (iii) a group of HFpEF patients that do not consistently cluster (NCC) among the machine learning techniques. These subgroups cannot be distinguished from the clinical data alone. However, reanalyzing the clinical data of each of these newly determined subgroups reveals that elevated systolic and diastolic LV volumes seen in both HFrEF and HFpEF1 may be used to identify HFrEF‐like HFpEF patients. Similar HFpEF groupings have been identified by other studies using specialized clinical measures (e.g., from non‐routine echocardiography and heart biopsies) whereas our study analyzes data from standard clinical procedures, such as TTE and RHC. Hence, our methodology has great translational potential to be broadly accepted in the clinic. These results suggest that physiology‐informed model‐based analysis of standard clinical data in conjunction with unsupervised machine learning can distinguish subgroups of HFpEF as separate phenotypes. Moreover, this methodology has the potential to retrospectively assess patient selection in past HFpEF clinical studies, aid in the optimization of prospective HFpEF subgroup selection for future clinical trials, and elucidate patient‐specific treatment strategies.

Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction

Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review

Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping

The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal

[Focus on heart failure with preserved ejection fraction: from trials to the real world of the Friuli-Venezia Giulia Cardiovascular Observatory]

Analysis Of Clinical, Biochemical And Echocardiographic Criteria For Heart Failure With Preserved Ejection Fraction

How to Deal with This Chameleon

Using Model‐Based Analysis and Physiology‐Informed Machine Learning to Refine the Stratification of Phenotypes in Heart Failure

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach

Characteristics, Prognosis and Treatment Response in Distinct Phenogroups of Heart Failure with Preserved Ejection Fraction.

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction

Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models

Pathophysiological insights into HFpEF from studies of human cardiac tissue

Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier

Heart failure with preserved ejection fraction: New challenges and new hopes